Lars Wortmann

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 12

Top Venues

Journal of medicinal chemistry

Angewandte Chemie (International ed. in English)

Molecular cancer therapeutics

Boehringer Ingelheim Pharma GmbH and Co KG Biberach

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Boehringer Ingelheim Pharma GmbH and Co KG Biberach May 01 2020

Germany

Principal Scientist :: Medicinal Chemistry

Bayer AG Jun 01 2001 - Apr 30 2020

Germany

Senior Scientist :: Medicinal Chemistry

Stanford University May 01 2000 - Apr 30 2001

United States

Postdoc :: Department of Chemistry

Publications

Sven Thamm, Marina K Willwacher, Gary E Aspnes, Tom Bretschneider, Nicholas F Brown, Silke Buschbom-Helmke, Thomas Fox, Emanuele M Gargano, Daniel Grabowski, Christoph Hoenke, Damian Matera, Katja Mueck, Stefan Peters, Sophia Reindl, Doris Riether, Matthias Schmid, Christofer S Tautermann, Aaron M Teitelbaum, Cornelius Trünkle, Thomas Veser, Martin Winter, Lars Wortmann
Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science. Journal of medicinal chemistry 66 (4) (2023)
Sven Thamm, Marina K Willwacher, Gary E Aspnes, Tom Bretschneider, Nicholas F Brown, Silke Buschbom-Helmke, Thomas Fox, Emanuele M Gargano, Daniel Grabowski, Christoph Hoenke, Damian Matera, Katja Mueck, Stefan Peters, Sophia Reindl, Doris Riether, Matthias Schmid, Christofer S Tautermann, Aaron M Teitelbaum, Cornelius Trünkle, Thomas Veser, Martin Winter, Lars Wortmann
Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science. Journal of medicinal chemistry (2023)
Sven Thamm, Marina K Willwacher, Gary E Aspnes, Tom Bretschneider, Nicholas F Brown, Silke Buschbom-Helmke, Thomas Fox, Emanuele M Gargano, Daniel Grabowski, Christoph Hoenke, Damian Matera, Katja Mueck, Stefan Peters, Sophia Reindl, Doris Riether, Matthias Schmid, Christofer S Tautermann, Aaron M Teitelbaum, Cornelius Trünkle, Thomas Veser, Martin Winter, Lars Wortmann
Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science. Journal of medicinal chemistry 66 (4) (2023)
Sven Thamm, Marina K Willwacher, Gary E Aspnes, Tom Bretschneider, Nicholas F Brown, Silke Buschbom-Helmke, Thomas Fox, Emanuele M Gargano, Daniel Grabowski, Christoph Hoenke, Damian Matera, Katja Mueck, Stefan Peters, Sophia Reindl, Doris Riether, Matthias Schmid, Christofer S Tautermann, Aaron M Teitelbaum, Cornelius Trünkle, Thomas Veser, Martin Winter, Lars Wortmann
Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science. Journal of medicinal chemistry 66 (4) (2023)
Sven Thamm, Marina K Willwacher, Gary E Aspnes, Tom Bretschneider, Nicholas F Brown, Silke Buschbom-Helmke, Thomas Fox, Emanuele M Gargano, Daniel Grabowski, Christoph Hoenke, Damian Matera, Katja Mueck, Stefan Peters, Sophia Reindl, Doris Riether, Matthias Schmid, Christofer S Tautermann, Aaron M Teitelbaum, Cornelius Trünkle, Thomas Veser, Martin Winter, Lars Wortmann
Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science. Journal of medicinal chemistry 66 (4) (2023)
Lars Wortmann, Nico Bräuer, Simon J Holton, Horst Irlbacher, Jörg Weiske, Christian Lechner, Robin Meier, Jakob Karén, Catrine Berthold Siöberg, Vera Pütter, Clara D Christ, Antonius Ter Laak, Philip Lienau, Ralf Lesche, Barbara Nicke, Shing-Hu Cheung, Marcus Bauser, Andrea Haegebarth, Franz von Nussbaum, Dominik Mumberg, Clara Lemos
Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A. Journal of medicinal chemistry 64 (21) (2021)
Markus Berger, Lars Wortmann, Philipp Buchgraber, Ulrich Lücking, Sabine Zitzmann-Kolbe, Antje M Wengner, Benjamin Bader, Ulf Bömer, Hans Briem, Knut Eis, Hartmut Rehwinkel, Florian Bartels, Dieter Moosmayer, Uwe Eberspächer, Philip Lienau, Stefanie Hammer, Christoph A Schatz, Qiuwen Wang, Qi Wang, Dominik Mumberg, Carl Friedrich Nising, Gerhard Siemeister
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies. Journal of medicinal chemistry 64 (17) (2021)
Laura M Luh, Ulrike Scheib, Katrin Juenemann, Lars Wortmann, Michael Brands, Philipp M Cromm
Prey for the Proteasome: Targeted Protein Degradation-A Medicinal Chemist's Perspective. Angewandte Chemie (International ed. in English) 59 (36) (2020)
Ulrich Lücking, Lars Wortmann, Antje M Wengner, Julien Lefranc, Philip Lienau, Hans Briem, Gerhard Siemeister, Ulf Bömer, Karsten Denner, Martina Schäfer, Marcus Koppitz, Knut Eis, Florian Bartels, Benjamin Bader, Wilhelm Bone, Dieter Moosmayer, Simon J Holton, Uwe Eberspächer, Joanna Grudzinska-Goebel, Christoph Schatz, Gesa Deeg, Dominik Mumberg, Franz von Nussbaum
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. Journal of medicinal chemistry 63 (13) (2020)
Duy Nguyen, Clara Lemos, Lars Wortmann, Knut Eis, Simon J Holton, Ulf Boemer, Dieter Moosmayer, Uwe Eberspaecher, Joerg Weiske, Christian Lechner, Stefan Prechtl, Detlev Suelzle, Franziska Siegel, Florian Prinz, Ralf Lesche, Barbara Nicke, Katrin Nowak-Reppel, Herbert Himmel, Dominik Mumberg, Franz von Nussbaum, Carl F Nising, Marcus Bauser, Andrea Haegebarth
Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5. Journal of medicinal chemistry 62 (2) (2019)
Antje M Wengner, Gerhard Siemeister, Ulrich Lücking, Julien Lefranc, Lars Wortmann, Philip Lienau, Benjamin Bader, Ulf Bömer, Dieter Moosmayer, Uwe Eberspächer, Sven Golfier, Christoph A Schatz, Simon J Baumgart, Bernard Haendler, Pascale Lejeune, Andreas Schlicker, Franz von Nussbaum, Michael Brands, Karl Ziegelbauer, Dominik Mumberg
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models. Molecular cancer therapeutics 19 (1) (2019)
Lars Wortmann, Bernhard Lindenthal, Peter Muhn, Alexander Walter, Reinhard Nubbemeyer, Dieter Heldmann, Lothar Sobek, Federica Morandi, Anna K Schrey, Dieter Moosmayer, Judith Günther, Joachim Kuhnke, Marcus Koppitz, Ulrich Lücking, Ulrike Röhn, Martina Schäfer, Katrin Nowak-Reppel, Ronald Kühne, Hilmar Weinmann, Gernot Langer
Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in Vivo. Journal of medicinal chemistry 62 (22) (2019)

Lars Wortmann.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Lars Wortmann